Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir

British Journal of Pharmacology

Volumn 169, Issue 1, 2013, Pages 115-129

  Hiasa, Miki ^a   Isoda, Yumiko ^a   Kishimoto, Yasushi ^a   Saitoh, Kenta ^b   Kimura, Yasuaki ^b   Kanai, Motomu ^b   Shibasaki, Masakatsu ^c   Hatakeyama, Dai ^a   Kirino, Yutaka ^a   Kuzuhara, Takashi ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

monoamine oxidase; oseltamivir; prodrug; stimulated behaviour

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; OSELTAMIVIR; OSELTAMIVIR ETHYL ESTER; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; JUMPING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REARING; SNIFFING; WALKING;

ANIMALS; ANTIVIRAL AGENTS; BEHAVIOR, ANIMAL; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OSELTAMIVIR; PRODRUGS; VIDEO RECORDING;

EID: 84876231297     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12102     Document Type: Article

References (62)

1. Abdel-Rahman SM, Newland JG, Kearns GL, (2011). Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr Drugs 13: 19-31.
2. Bonivento D, Milczek EM, McDonald GR, Binda C, Holt A, Edmondson DE, et al. (2010). Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J Biol Chem 285: 36849-36856.
3. Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, et al. (1989). Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 391-399.
4. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al. (2002). Role of genotype in the cycle of violence in maltreated children. Science 297: 851-854.
5. Chen K, Holschneider DP, Wu W, Rebrin I, Shih JC, (2004). A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. J Biol Chem 279: 39645-39652.
6. Chung S, Joung YS, (2010). Oseltamivir (Tamiflu) induced depressive episode in a female adolescent. Psychiatry Investig 7: 302-304.
7. Crabb DW, Matsumoto M, Chang D, You M, (2004). Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 63: 49-63.
8. Crain SM, Shen KF, (2004). Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res 995: 260-266.
9. De Clercq E, (2006). Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5: 1015-1025.
10. Dixon M, Webb EC, (1979). Enzymes, 3rd edn. Longman Group Ltd.: London.
11. Donner B, Bader-Weder S, Schwarz R, Peng MM, Smith JR, Niranjan V, (2011). Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf 20: 532-543.
12. El-Sayed WM, Al-Kahtani MA, (2011). Potential adverse effects of oseltamivir in rats: males are more vulnerable than females. Can J Physiol Pharmacol 89: 623-630.
13. Freichel C, Breidenbach A, Hoffmann G, Körner A, Gatti S, Donner B, et al. (2012). Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat. Basic Clin Pharmacol Toxicol 111: 50-57.
14. Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC, (1999). Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter. Am J Med Genet 88: 398-406.
15. Goto J, Kataoka R, (2008). ASEDock-Docking based on alpha spheres and excluded volumes. J Chem Inf Model 48: 583-590.
16. Guzmán DC, García EH, Brizuela NO, Jiménez FT, Mejía GB, Olguín HJ, et al. (2010). Effect of oseltamivir on catecholamines and select oxidative stress markers in the presence of oligoelements in the rat brain. Arch Pharm Res 33: 1671-1677.
17. Haley TJ, McCormick WG, (1957). Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12: 12-15.
18. Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, et al. (2008). Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother 52: 3484-3491.
19. 11C]Ro 64-0802 in mice. Nucl Med Biol 36: 47-55.
20. 11C]oseltamivir using PET and autoradiography. Neurosci Lett 495: 187-191.
21. Hirabayashi M, Iwai F, Iizuka M, Mesaki T, Alam MR, Tadokoro S, (1979). Individual differences in the accelerating effect of methamphetamine, d-amphetamine and morphine on ambulatory activity in mice. Folia Pharmacol Jpn 75: 683-693.
22. Iwai Y, Murakami K, Gomi Y, Hashimoto T, Asakawa Y, Okuno Y, et al. (2011). Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. PLoS ONE 6: e19825.
23. Izumi Y, Tokuda K, O'Dell KA, Zorumski CF, Narahashi T, (2007). Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 426: 54-58.
24. Izumi Y, Tokuda K, O'Dell K, Zorumski C, Narahashi T, (2008). Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants. Hum Exp Toxicol 27: 911-917.
25. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A, (2006). Antivirals for influenza in healthy adults: systematic review. Lancet 367: 303-313.
26. Jefferson T, Jones M, Doshi P, Del Mar C, (2009). Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 339: b5106.
27. Kadowaki T, Komagamine T, Suzuki K, Hirata K, (2011). Oseltamivir-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 17: 133-134.
28. Kaji M, Fukuda T, Tanaka M, Aizawa H, (2005). A side effect of neuraminidase inhibitor in a patient with liver cirrhosis. J Infect Chemother 11: 41-43.
29. Kamal MA, Greig NH, Alhomida AS, Al-Jafari AA, (2000). Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. Biochem Pharmacol 60: 561-570.
30. Kishimoto Y, Higashihara E, Fukuta A, Nagao A, Kirino Y, (2013). Early impairment in a water-finding test in a longitudinal study of the Tg2576 mouse model of Alzheimer's disease. Brain Res 1491: 117-126.
31. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H, (2009). Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009-an internet-based cross-sectional survey. Euro Surveill 14: 2-5.
32. L'Huillier AG, Lorenzini KI, Crisinel PA, Rebsamen MC, Fluss J, Korff CM, et al. (2011). ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. Pharmacogenomics 12: 1493-1501.
33. Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG, et al. (2010). In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 628: 6-10.
34. McNamara RK, Logue A, Stanford K, Xu M, Zhang J, Richtand NM, (2006). Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse 60: 399-405.
35. Maxwell SR, (2007). Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 334: 1232-1233.
36. Medina RA, García-Sastre A, (2011). Influenza A viruses: new research developments. Nat Rev Microbiol 9: 590-603.
37. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63: 1209-1216.
38. Moscona A, (2005). Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373.
39. Nakamura K, Schwartz BS, Lindegårdh N, Keh C, Guglielmo BJ, (2010). Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis 50: e47-e49.
40. Neumann G, Noda T, Kawaoka Y, (2009). Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
41. Ose A, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T, et al. (2008). P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos 36: 427-434.
42. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, et al. (2009). Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1- ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 37: 315-321.
43. Oshima S, Nemoto E, Kuramochi M, Saitoh Y, Kobayashi D, (2009). Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice. J Pharm Pharmacol 61: 1397-1400.
44. Reagan-Shaw S, Nihal M, Ahmad N, (2008). Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
45. Roughan JV, Wright-Williams SL, Flecknell PA, (2009). Automated analysis of postoperative behaviour: assessment of HomeCageScan as a novel method to rapidly identify pain and analgesic effects in mice. Lab Anim 43: 17-26.
46. Sabol SZ, Hu S, Hamer D, (1998). A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103: 273-279.
47. Satoh K, Nonaka R, Ogata A, Nakae D, Uehara S, (2007). Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. Biol Pharm Bull 30: 1816-1818.
48. Shih JC, Chen K, Ridd MJ, (1999). Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22: 197-217.
49. Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T, (2008). Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci U S A 105: 5739-5744.
50. Suzuki M, Masuda Y, (2008). Effect of a neuraminidase inhibitor (oseltamivir) on mouse jump-down behavior via stimulation of dopamine receptors. Biomed Res 29: 233-238.
51. 11C-oseltamivir. J Nucl Med 52: 950-957.
52. Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M, (2012). Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther 92: 68-71.
53. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, et al. (2008). Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 31: 1097-1114.
54. Uchiyama H, Toda A, Imoto M, Nishimura S, Kuroki H, Soeda S, et al. (2010). The stimulatory effects of caffeine with oseltamivir (Tamiflu) on light-dark behavior and open-field behavior in mice. Neurosci Lett 469: 184-188.
55. Usami A, Sasaki T, Satoh N, Akiba T, Yokoshima S, Fukuyama T, et al. (2008). Oseltamivir enhances hippocampal network synchronization. J Pharmacol Sci 106: 659-662.
56. Valley MP, Zhou W, Hawkins EM, Shultz J, Cali JJ, Worzella T, et al. (2006). A bioluminescent assay for monoamine oxidase activity. Anal Biochem 359: 238-246.
57. Wang S, Le TQ, Kurihara N, Chida J, Cisse Y, Yano M, et al. (2010). Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 202: 991-1001.
58. Yoshino T, Nisijima K, Shioda K, Yui K, Kato S, (2008). Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci Lett 438: 67-69.
59. Youdim MB, Bakhle YS, (2006). Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 (Suppl. 1): S287-S296.
60. Youdim MB, Edmondson D, Tipton KF, (2006). The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7: 295-309.
61. Zhu HJ, Markowitz JS, (2009). Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos 37: 264-267.
62. Zhu HJ, Appel DI, Jiang Y, Markowitz JS, (2009). Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos 37: 1819-1825.